NASDAQ:SLRX Salarius Pharmaceuticals (SLRX) Stock Price, News & Analysis $1.56 +0.02 (+1.30%) (As of 04:26 PM ET) Add Compare Share Share Today's Range$1.53▼$1.6350-Day Range$1.46▼$3.7352-Week Range$1.35▼$7.60Volume25,911 shsAverage Volume872,306 shsMarket Capitalization$931,320.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Salarius Pharmaceuticals alerts: Email Address Salarius Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.13% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.43Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($214.40) to ($188.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.07 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Salarius Pharmaceuticals.Read more about Salarius Pharmaceuticals' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.13% of the float of Salarius Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSalarius Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Salarius Pharmaceuticals has recently decreased by 64.00%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSalarius Pharmaceuticals does not currently pay a dividend.Dividend GrowthSalarius Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SLRX. Previous Next 3.0 News and Social Media Coverage News SentimentSalarius Pharmaceuticals has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Salarius Pharmaceuticals this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for SLRX on MarketBeat in the last 30 days. This is a decrease of -94% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Salarius Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.50% of the stock of Salarius Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 11.88% of the stock of Salarius Pharmaceuticals is held by institutions.Read more about Salarius Pharmaceuticals' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Salarius Pharmaceuticals are expected to grow in the coming year, from ($214.40) to ($188.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Salarius Pharmaceuticals is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Salarius Pharmaceuticals is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSalarius Pharmaceuticals has a P/B Ratio of 0.15. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Salarius Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… Elon Musk just built a supercomputer in Memphis, Tennessee. It took him only 122 days. Dubbed “Colossus,” this supercomputer aims to become the most powerful AI training system in the world. Housed in a 785,000 sq. ft facility in Memphis, Colossus will soon require 150 megawatts of electricity per day. That’s about equal to the amount of energy needed to power 100,000 homes per year. Click here and take notes. About Salarius Pharmaceuticals Stock (NASDAQ:SLRX)Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.Read More SLRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLRX Stock News HeadlinesAugust 12, 2024 | investorplace.comSLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q2 2024July 30, 2024 | benzinga.com(SLRX) - Analyzing Salarius Pharmaceuticals's Short InterestSeptember 13, 2024 | Porter & Company (Ad)War on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.July 25, 2024 | benzinga.comWhy Edwards Lifesciences Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day SessionJuly 23, 2024 | investorplace.comWhy Is Salarius Pharmaceuticals (SLRX) Stock Up 90% Today?July 23, 2024 | investorplace.comWhy Is Salarius Pharmaceuticals (SLRX) Stock Up 90% Today?July 19, 2024 | barrons.comSalarius Pharmaceuticals Inc.July 19, 2024 | benzinga.comSalarius Pharmaceuticals (NASDAQ:SLRX) Stock, Short Interest ReportSeptember 13, 2024 | Porter & Company (Ad)War on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.June 12, 2024 | globenewswire.comSalarius Pharmaceuticals Announces 1-for-8 Reverse Stock SplitMay 14, 2024 | investorplace.comSLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q1 2024April 2, 2024 | finance.yahoo.comSLRX Pursues Important GoalMarch 27, 2024 | msn.comWall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation DataMarch 25, 2024 | msn.comWhy Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving PremarketMarch 23, 2024 | finanznachrichten.deSalarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 22, 2024 | sfgate.comSalarius: Q4 Earnings SnapshotMarch 22, 2024 | globenewswire.comSalarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 5, 2024 | msn.comQuoin stock craters 47% on public offering after rallying in prior sessionSee More Headlines Receive SLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Salarius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2024Today9/13/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SLRX CUSIPN/A CIK1615219 Webwww.salariuspharma.com Phone(832) 834-6992FaxN/AEmployees20Year Founded2011Profitability EPS (Most Recent Fiscal Year)($21.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,540,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-148.63% Return on Assets-110.36% Debt Debt-to-Equity RatioN/A Current Ratio2.98 Quick Ratio2.98 Sales & Book Value Annual Sales$1.84 million Price / Sales0.52 Cash FlowN/A Price / Cash FlowN/A Book Value$10.74 per share Price / Book0.15Miscellaneous Outstanding Shares597,000Free Float564,000Market Cap$961,170.00 OptionableNot Optionable Beta0.95 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. David J. Arthur M.B.A. (Age 61)CEO, President & Director Comp: $343.2kMr. Mark J. Rosenblum CPA (Age 71)Executive VP of Finance & CFO Key CompetitorsMedAvailNASDAQ:MDVLVirios TherapeuticsNASDAQ:VIRISunshine BiopharmaNASDAQ:SBFMTrevenaNASDAQ:TRVNTharimmuneNASDAQ:THARView All CompetitorsInstitutional OwnershipArmistice Capital LLCSold 61,250 shares on 8/15/2024Ownership: 3.811%View All Institutional Transactions SLRX Stock Analysis - Frequently Asked Questions How have SLRX shares performed this year? Salarius Pharmaceuticals' stock was trading at $5.20 on January 1st, 2024. Since then, SLRX stock has decreased by 69.0% and is now trading at $1.61. View the best growth stocks for 2024 here. How were Salarius Pharmaceuticals' earnings last quarter? Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) posted its quarterly earnings results on Friday, August, 9th. The company reported ($2.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($53.60) by $51.23. When did Salarius Pharmaceuticals' stock split? Salarius Pharmaceuticals shares reverse split on the morning of Monday, June 17th 2024. The 1-8 reverse split was announced on Monday, June 17th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. Who are Salarius Pharmaceuticals' major shareholders? Top institutional shareholders of Salarius Pharmaceuticals include Armistice Capital LLC (3.81%). Insiders that own company stock include David J Arthur, Mark J Rosenblum, Arnold C Hanish and William K Mcvicar. View institutional ownership trends. How do I buy shares of Salarius Pharmaceuticals? Shares of SLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Salarius Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Salarius Pharmaceuticals investors own include Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Arbutus Biopharma (ABUS), Fulcrum Therapeutics (FULC), Allena Pharmaceuticals (ALNA) and Biocept (BIOC). This page (NASDAQ:SLRX) was last updated on 9/13/2024 by MarketBeat.com Staff From Our PartnersYou won’t believe what this ex-Wall Street insider discovered about the electionOne ex-Wall Street insider recently combed through 64 years of election data… And he just uncovered somethi...Banyan Hill Publishing | Sponsored Turn Smartphones Into “Earnphones”?High-Growth Smartphone Startup 45 Million Users. $60M+ in Revenue. 32,481% Growth Rate. $1T+ market opportu...Mode Mobile | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTiny Defense Firm Set for Huge Gains with New US ContractOne tiny defense firm just won a groundbreaking US military contract… That could hand early investors gains...Behind the Markets | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredPlace this $0.99 trade BEFORE the electionEarlier this year, Millionaire Trader Nate Bear of Monument Traders Alliance went live in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Salarius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Salarius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
